Earnings Releases·Nov 10, 2026, 4:28 PM ET

Inhibikase Therapeutics — Third Quarter 2026 Earnings Summary

Net loss for the quarter ended September 30, 2026, widened to $20.5 million ($0.10 per share) from $11.9 million ($0.13 per share) in the prior year period, driven by a 97% year-over-year increase in research and development expenses to $15.0 million.
The Company raised $50 million in July 2026 via an at-the-market facility and maintains $193.3 million in cash and marketable securities, which management states will support operations through the Part B IMPROVE-PAH topline data readout assuming full exercise of outstanding Series A and B Warrants.
The Phase 3 IMPROVE-PAH study has secured regulatory approvals in 28 countries with 79 of 180 sites activated; an interim safety readout for Part A is scheduled for the first half of 2027, with nonclinical combination therapy results expected progressively starting in Q1 2027.
The Board of Directors was expanded in October 2026 with the appointment of Scott M. Wasserman, MD, a cardiologist and former Chief Medical Officer of Kailera Therapeutics, while the Company continues to advance regulatory filings for combination therapy with sotatercept.